



Prior Authorization Approval Criteria

Ambien CR (zolpidem, extended release)

Generic name:	Zolpidem, extended release
Brand name:	Ambien CR
Medication class:	Hypnotic
FDA-approved uses:	Treatment of insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.
Available dosage forms:	6.25 mg and 12.5 mg tablets
Usual dose:	12.5 mg immediately before bedtime. 6.25 mg is recommended for the elderly or those with hepatic insufficiency.
Duration of therapy:	Indefinite

Criteria for use (*bullet points below are all inclusive unless otherwise noted*):

- Quantity limit of nine pills per month.
- Clinically diagnosed insomnia.
- Treatment failure on one of these products (oxazepam, temazepam, lorazepam, alprazolam, diazepam, flurazepam, trazodone).
- Treatment failure on Ambien.
- Underlying physical or psychological conditions (including addiction, depression, anxiety, sleep apnea, restless leg syndrome, circadian issues, pain, GERD, etc.) have been ruled out or are being adequately treated.

Contraindication: Hypersensitivity to zolpidem products.

Not approved if:

- Does not meet the above-stated criteria.
- Have any contraindications to the use of zolpidem.

FCHP Pharmacy and Therapeutics Committee approval: _____

Date: _____

Adopted: 3/16/2006

Revised: 12/08